体外受精与卵胞浆内单精子注射随机对照试验中的选择性结局报告与赞助情况
系统检索2009年1月至2016年3月发表的415项体外受精与卵胞浆内单精子注射随机对照试验,分析180项报告了赞助情况的试验。结果显示62%的试验使用替代主要结局指标,18%的注册试验在论文中报告的主要结局与注册信息不一致,且选择性结局报告与赞助无关。
要点
- 180项试验中107项(62%)使用替代主要结局指标。
- 114项注册试验中21项(18%)论文主要结局与注册信息不同。
- 未发现选择性结局报告与赞助之间存在关联。
核心结论
- 体外受精与卵胞浆内单精子注射随机对照试验在很大程度上存在选择性结局报告,且与赞助无关。
研究设计与样本
- 系统检索MEDLINE、EMBASE、Cochrane对照试验中心注册库和PubMed出版商子集中2009年1月至2016年3月发表的体外受精与卵胞浆内单精子注射随机对照试验,共分析415项试验。
主要发现
- 415项试验中235项因未报告赞助情况被排除于主要分析,180项纳入分析。
- 纳入分析的180项试验中7项未报告任何主要结局指标,剩余173项中107项(62%)报告了替代主要结局指标。
- 114项注册试验中21项(18%)在论文中提供的主要结局与试验注册信息不同。
- 未发现选择性结局报告与赞助之间存在关联。
- 纳入未报告赞助的试验进行额外分析,结果与主要分析无差异。
局限性
- 由于大多数试验未报告赞助情况,存在抽样偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are randomized controlled trials (RCTs) on IVF and ICSI subject to selective outcome reporting and is this related to sponsorship? SUMMARY ANSWER: There are inconsistencies, independent from sponsorship, in the reporting of primary outcome measures in the majority of IVF and ICSI trials, indicating selective outcome reporting. WHAT IS KNOWN ALREADY: RCTs are subject to bias at various levels. Of these biases, selective outcome reporting is particularly relevant to IVF and ICSI trials since there is a wide variety of outcome measures to choose from. An established cause of reporting bias is sponsorship. It is, at present, unknown whether RCTs in IVF/ICSI are subject to selective outcome reporting and whether this is related with sponsorship. STUDY DESIGN, SIZE, DURATION: We systematically searched RCTs on IVF and ICSI published between January 2009 and March 2016 in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and the publisher subset of PubMed. We analysed 415 RCTs. PARTICIPANTS/MATERIALS, SETTING, METHODS: Per included RCT, we extracted data on impact factor of the journal, sample size, power calculation, and trial registry and thereafter data on primary outcome measure, the direction of trial results and sponsorship. MAIN RESULTS AND THE ROLE OF CHANCE: Of the 415 identified RCTs, 235 were excluded for our primary analysis, because the sponsorship was not reported. Of the 180 RCTs included in our analysis, 7 trials did not report on any primary outcome measure and 107 of the remaining 173 trials (62%) reported on surrogate primary outcome measures. Of the 114 registered trials, 21 trials (18%) provided primary outcomes in their manuscript that were different from those in the trial registry. This indicates selective outcome reporting. We found no association between selective outcome reporting and sponsorship. We ran additional analyses to include the trials that had not reported sponsorship and found no outcomes that differed from our primary analysis. LIMITATIONS, REASONS FOR CAUTION: Since the majority of the trials did not report on sponsorship, there is a risk on sampling bias. WIDER IMPLICATIONS OF THE FINDINGS: IVF and ICSI trials are subject, to a large extent, to selective outcome reporting. Readers should be aware of this to avoid implementation of false or misleading results in clinical practice. STUDY FUNDING/COMPETING INTERESTS: No funding received and there are no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Braakhekke M, Scholten I, Mol F, et al. Selective outcome reporting and sponsorship in randomized controlled trials in IVF and ICSI. Hum Reprod. 2017. PMID: 28938740. doi:10.1093/humrep/dex273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。